
    
      Study entry requires a diagnosis of low or intermediate (INT-1) risk MDS per International
      Prognostic Scoring System (IPSS) criteria and serum ferritin â‰¥ 1000 ng/mL. Patients must have
      had at least 30 prior red blood cell transfusions. Deferasirox will be administered at an
      initial dose of 20 mg/kg orally once per day. Patient transfusion history and at least three
      complete blood count (CBC) values must be available for the 12 weeks prior to study
      registration for patients with MDS and chronic iron overload from blood transfusions.
    
  